← Back to Clinical Trials
Recruiting NCT06917053

NCT06917053 Renal Perfusion and the Development of AKI Following Traumatic Injury

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06917053
Status Recruiting
Phase
Sponsor King's College Hospital NHS Trust
Condition Traumatic Haemorrhagic Shock
Study Type OBSERVATIONAL
Enrollment 20 participants
Start Date 2024-04-13
Primary Completion 2026-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Ultrasound (including contrast enhanced ultrasound)Sublingual incident dark field videomicroscopyUrinary oxygen tension.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20 participants in total. It began in 2024-04-13 with a primary completion date of 2026-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Acute kidney injury (AKI) is a complication of traumatic haemorrhagic shock (THS) and together these conditions increase mortality risk. Although septic shock patients who develop severe AKI are known to develop hypoperfusion of the renal cortex, little is known regarding intra-renal perfusion changes in THS. The aim of the current study is to investigate the effects of THS on renal microcirculatory perfusion.

Eligibility Criteria

Inclusion Criteria: * Age \> 18 years * Within 24 hours of ICU admission following traumatic injury * Received any blood products during initial resuscitation * Lactate \> 2 mmol/l at any stage prior to study enrolment Exclusion Criteria: * Known intolerance to Sonovue or any other ultrasound contrast agent * Patients with un-survivable injuries / not expected to survive 24 hours in whom the intent of treatment is palliative * Known CKD 4 or end stage renal failure * Pregnancy

Contact & Investigator

Central Contact

Sam Hutchings

✉ sam.hutchings@nhs.net

📞 +442032994957

Frequently Asked Questions

Who can join the NCT06917053 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Traumatic Haemorrhagic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06917053 currently recruiting?

Yes, NCT06917053 is actively recruiting participants. Contact the research team at sam.hutchings@nhs.net for enrollment information.

Where is the NCT06917053 trial being conducted?

This trial is being conducted at London, United Kingdom.

Who is sponsoring the NCT06917053 clinical trial?

NCT06917053 is sponsored by King's College Hospital NHS Trust. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology